Procter & Gamble Health Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹364Cr
- +7.4% YoY
- −1.6% QoQ
- Net profit
- ₹96Cr
- +45.5% YoY
- +1.1% QoQ
- Margin
- 27%
- 0 pp YoY
- −10 pp QoQ
Guidance rank: #75 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Procter & Gamble Health Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
FY 2025-26 sales grew by +16% year-on-year, indicating strong consistent balanced growth (Page 8).
From Procter & Gamble Health Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- FY 2025-26 sales grew by +16% year-on-year, indicating strong consistent balanced growth (Page 8).
- Profit after tax (PAT) increased by +30% in the same period (Page 8).
- Net Sales showed a +7% CAGR over the past 5 years (Page 27).
- PAT grew at a +13% CAGR over 5 years (Page 27).
2 more points from Procter & Gamble Health Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Procter & Gamble Health Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Procter & Gamble Health Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Procter & Gamble Health Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Procter & Gamble Health Ltd said on order book & pipeline — free account, 30 seconds.
Procter & Gamble Health Ltd — Quarterly revenue & net profit
Procter & Gamble Health Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 364 | 339 | +7.4% | 370 | -1.6% |
| Operating profit (EBITDA) | 100 | 90 | +11.1% | 136 | -26.5% |
| Operating margin | 27% | 27% | 0 pp | 37% | -10 pp |
| Profit before tax | 129 | 89 | +44.9% | 133 | -3% |
| Net profit (PAT) | 96 | 66 | +45.5% | 95 | +1.1% |
| EPS (₹) | 57.92 | 39.87 | +45.3% | 56.99 | +1.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹382 Cr, net profit ₹112 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What P & G Health Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Procter & Gamble Health Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Procter & Gamble Health Ltd Q1 FY27 results?
FY 2025-26 sales grew by +16% year-on-year, indicating strong consistent balanced growth (Page 8).
What is Procter & Gamble Health Ltd share price analysis?
Procter & Gamble Health Ltd currently shows a neutral. The stock trades at a P/E of 27.4 with a market cap of ₹9,135 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Procter & Gamble Health Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
